Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review | SpringerLink
Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma
Third-line therapy for chronic myeloid leukemia: current status and future directions | Journal of Hematology & Oncology | Full Text
Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein | Leukemia
Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram
Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer | EMBO Molecular Medicine
Anti-Alpha-Synuclein Therapies in Parkinson's Disease - Practical Neurology
Chemical structures of the ATP competitors imatinib, nilotinib,... | Download Scientific Diagram
Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium - Journal of the Neurological Sciences
Proposed mechanism of nilotinib in the regulation of pigmentation.... | Download Scientific Diagram
5MJC BCU 13: Tyrosine Kinases as Targets for Cancer Therapy | Research To Practice
Chronic Myeloid Leukemia - ppt video online download
Imatinib - Wikipedia
Why I Do Buy Biotech | Seeking Alpha
Nilotinib - Wikipedia
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. - Abstract - Europe PMC
Current status of therapy for chronic myeloid leukemia: a review of drug development | Future Oncology
Modern Therapy of Chronic Myeloid Leukemia | IntechOpen
Pharmacology of Drugs: Nilotinib
Frontiers | Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation | Oncology
Nilotinib | C28H22F3N7O - PubChem
Proposed mechanism of nilotinib in the regulation of pigmentation.... | Download Scientific Diagram
Cells | Free Full-Text | Nilotinib: A Tyrosine Kinase Inhibitor Mediates Resistance to Intracellular Mycobacterium Via Regulating Autophagy | HTML
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors - ScienceDirect
Mechanism of action of BCR (breakpoint cluster region)-ABL (Abelson 1... | Download Scientific Diagram
